US · TLSI
TriSalus Life Sciences, Inc.
- Sector
- Healthcare · Medical - Devices
- Headquarters
- Westminster, CO 80031
- Website
- trisaluslifesci.com
Price · as of 2024-12-31
$4.39
Market cap 167.17M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $32.74 | +645.79% |
| Intrinsic Value(DCF) | $94.25 | +2,046.92% |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | |||||
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | |||||
| 2016 | |||||
| 2017 | |||||
| 2018 | |||||
| 2019 | |||||
| 2020 | $9.88 | ||||
| 2021 | $9.78 | ||||
| 2022 | $10.20 | $27.99 | $4.79 | $0.00 | $0.00 |
| 2023 | $10.00 | $25.97 | $0.00 | $0.00 | $0.00 |
| 2024 | $5.36 | $32.74 | $141.39 | $0.00 | $0.00 |
AI valuation
Our deep-learning model estimates TriSalus Life Sciences, Inc.'s (TLSI) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $32.74
- Current price
- $4.39
- AI upside
- +645.79%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$94.25
+2,046.92% upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| TLSI | TriSalus Life Sciences, I… | $4.39 | 167.17M | +646% | +2,047% | — | — | -4.73 | -5.49 | 4.83 | -4.35 | — | -5.49 | 86.06% | -122.88% | -112.92% | 113.47% | 150.57% | -123.72% | -0.91 | -11.70 | 2.02 | 1.33 | -0.42 | -4395.00% | 5899.00% | -1950.00% | -29.00% | -3.99 | 171.48% | 0.00% | 0.00% | 0.00% | -4.35 | -3.82 | 5.34 | -17.85 |
| AVR | Anteris Technologies Glob… | $6.51 | 239.49M | +229% | -58% | — | +1,116% | -1.66 | -1678.27 | 81.59 | -1.58 | -27.15 | -987.84 | 70.26% | 24.41% | -4925.51% | -300.71% | -5.60% | -181.73% | -24.54 | 6.40 | 0.73 | 0.59 | 0.11 | 610.00% | -2923.00% | 2251.00% | -49.85% | -3.64 | 932.39% | 0.00% | 0.00% | 0.00% | 312.17 | -1.87 | 76.21 | -18.68 |
| LNSR | LENSAR, Inc. | $11.97 | 142.98M | +705% | -42% | — | — | -5.45 | 9.18 | 3.20 | -50.35 | -5.03 | 13.66 | 48.33% | -19.94% | -58.71% | -95.42% | -88.05% | -46.22% | 0.14 | — | 2.80 | 1.93 | 4.54 | 10840.00% | 2687.00% | -7543.00% | -1.42% | -0.15 | -20.07% | 0.00% | 0.00% | 0.00% | -14.19 | -62.24 | 2.83 | -0.11 |
| MXCT | MaxCyte, Inc. | $0.81 | 86.54M | +3,073% | +164% | -99% | — | -8.96 | 1.78 | 9.53 | -4.99 | -165.84 | 1.78 | 81.62% | -132.54% | -106.29% | -18.73% | -67.18% | -16.17% | 0.09 | — | 10.88 | 10.09 | 0.21 | 541.00% | -644.00% | 1526.00% | -7.95% | -1.75 | -38.39% | 0.00% | 0.00% | 0.00% | -4.52 | -7.91 | 6.00 | 5.62 |
| NNOX | Nano-X Imaging Ltd. | $2.37 | 151.12M | +990% | +2% | — | — | -6.62 | 1.87 | 31.38 | -6.41 | — | 2.97 | -94.03% | -502.93% | -474.31% | -27.83% | -46.04% | -24.97% | 0.04 | — | 5.63 | 5.37 | 0.71 | -1574.00% | 1391.00% | -1813.00% | -11.12% | -2.62 | -32.15% | 0.00% | 0.00% | 0.00% | -5.08 | -7.32 | 25.55 | 7.21 |
| OWLT | Owlet, Inc. | $11.55 | 184.81M | +401% | +393% | — | — | -5.81 | -3.44 | 0.93 | -6.80 | — | -3.29 | 50.36% | -25.90% | -16.06% | 49.33% | 68.11% | -26.78% | -0.56 | -12.40 | 1.27 | 0.89 | 0.88 | -8168.00% | 4452.00% | -4925.00% | -16.44% | -0.31 | 40.32% | 0.00% | 0.00% | 11.27% | -3.19 | -5.38 | 0.83 | -6.50 |
| PRE | Prenetics Global Limited | $16.91 | 237.65M | +204% | +11,114% | — | — | -4.22 | 1.27 | 2.41 | -4.86 | -30.15 | 1.71 | 52.98% | -40.46% | -63.13% | -30.55% | -32.70% | -25.27% | 0.01 | -155.12 | 3.01 | 2.33 | 0.89 | 1401.00% | 20172.00% | -2645.00% | -9.89% | -0.79 | -19.26% | 0.00% | 0.00% | 0.00% | -4.37 | -7.42 | 1.77 | 4.78 |
| PROF | Profound Medical Corp. | $7.61 | 229.84M | +279% | -61% | — | — | -6.11 | 2.81 | 16.71 | -4.69 | — | 2.82 | 65.89% | -309.57% | -260.45% | -60.70% | -267.75% | -48.72% | 0.08 | — | 10.52 | 9.44 | 1.95 | -2074.00% | 4123.00% | 373.00% | -13.80% | -3.57 | -199.52% | 0.00% | 0.00% | 18.51% | -3.82 | -5.12 | 11.81 | 5.24 |
| STIM | Neuronetics, Inc. | $1.34 | 91.77M | +1,696% | +34,643% | — | — | -3.68 | 5.81 | 2.15 | -6.51 | -11.71 | -15.27 | 72.32% | -46.15% | -58.36% | -141.29% | -54.52% | -34.06% | 2.98 | -4.74 | 1.86 | 1.41 | -1.84 | 3143.00% | 496.00% | -565.00% | -20.18% | -0.99 | -51.22% | 0.00% | 0.00% | 0.00% | -6.48 | -6.90 | 2.99 | -3.34 |
About TriSalus Life Sciences, Inc.
TriSalus Life Sciences, Inc., an immunotherapy company that develops and commercializes immunotherapies for the treatment of liver and pancreatic tumors. The company offers the TriNav Infusion System for hepatic arterial infusion of liver tumors; and the Pancreatic Retrograde Venous Infusion System for pancreatic tumors. It also develops SD-101, an investigational immunotherapeutic with pressure-enabled drug delivery technology for hepatocellular carcinoma, intrahepatic cholangiocarcinoma, uveal melanoma with liver metastases, pancreatic ductal adenocarcinoma with liver metastases, colorectal cancer with liver metastases, and primary pancreatic cancers. The company is based in Westminster, Colorado.
- CEO
- Mary T. Szela
- Employees
- 110
- Beta
- 0.42
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($94.25 ÷ $4.39) − 1 = +2,046.92% (DCF, example).